Search Results - "Fumoleau, Pierre"

The paradox of triple negative breast cancer: novel approaches to treatment by Fornier, Monica, Fumoleau, Pierre

“…Breast cancer that lacks expression of estrogen/progesterone receptors and overexpression of the human epidermal growth factor receptor2 (HER2), i.e…”
Get more information

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy by BASELGA, José, GELMON, Karen A, FUMOLEAU, Pierre, GIANNI, Luca, VERMA, Shailendra, WARDLEY, Andrew, CONTE, Pierfranco, MILES, David, BIANCHI, Giulia, CORTES, Javier, MCNALLY, Virginia A, ROSS, Graham A

“…PURPOSE; Pertuzumab, a human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated…”
Get full text

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer by WOLFF, Antonio C, LAZAR, Ann A, CHAN, Arlene, HACHEMI, Soulef, STRAHS, Andrew, CINCOTTA, Maria, BERKENBLIT, Anna, KRYGOWSKI, Mizue, KANG, Lih Lisa, MOORE, Laurence, HAYES, Daniel F, BONDARENKO, Igor, GARIN, August M, BRINCAT, Stephen, CHOW, Louis, YAN SUN, NESKOVIC-KONSTANTINOVIC, Zora, GUIMARAES, Rodrigo C, FUMOLEAU, Pierre

“…Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane in patients with advanced breast cancer experiencing…”
Get full text

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial by Pivot, Xavier, Prof, Romieu, Gilles, MD, Debled, Marc, MD, Pierga, Jean-Yves, Prof, Kerbrat, Pierre, Prof, Bachelot, Thomas, MD, Lortholary, Alain, MD, Espié, Marc, MD, Fumoleau, Pierre, Prof, Serin, Daniel, MD, Jacquin, Jean-Philippe, MD, Jouannaud, Christelle, MD, Rios, Maria, MD, Abadie-Lacourtoisie, Sophie, MD, Tubiana-Mathieu, Nicole, Prof, Cany, Laurent, MD, Catala, Stéphanie, MD, Khayat, David, Prof, Pauporté, Iris, PhD, Kramar, Andrew, PhD

“…Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer…”
Get full text

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells by LADOIRE, Sylvain, ARNOULD, Laurent, APETOH, Lionel, COUDERT, Bruno, MARTIN, Francois, CHAUFFERT, Bruno, FUMOLEAU, Pierre, GHIRINGHELLI, Francois

“…Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess the capacity of neoadjuvant chemotherapy to affect T-cell…”
Get full text

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer by CORTES, Javier, FUMOLEAU, Pierre, SALVAGNI, Stefania, SERVENT, Veronique, GIANNI, Luca, SCALTRITI, Maurizio, ROSS, Graham A, DIXON, Joanna, SZADO, Tania, BASELGA, José, VALERIA BIANCHI, Giulia, PETRELLA, Teresa M, GELMON, Karen, PIVOT, Xavier, VERMA, Shailendra, ALBANELL, Joan, CONTE, Pierfranco, LLUCH, Ana

“…The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)…”
Get full text

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival by Ladoire, Sylvain, Mignot, Grégoire, Dabakuyo, Sandrine, Arnould, Laurent, Apetoh, Lionel, Rébé, Cedric, Coudert, Bruno, Martin, Francois, Bizollon, Marie Hélène, Vanoli, André, Coutant, Charles, Fumoleau, Pierre, Bonnetain, Franck, Ghiringhelli, François

“…Accumulating preclinical evidence suggests that anticancer immune responses contribute to the success of chemotherapy. However, the predictive value of…”
Get full text

Exosomes in cancer theranostic: Diamonds in the rough by Cordonnier, Marine, Chanteloup, Gaëtan, Isambert, Nicolas, Seigneuric, Renaud, Fumoleau, Pierre, Garrido, Carmen, Gobbo, Jessica

“…During the last 10 years, exosomes, which are small vesicles of 50-200 nm diameter of endosomal origin, have aroused a great interest in the scientific and…”
Get full text

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens by VALERO, Vicente, FORBES, John, FUMOLEAU, Pierre, ROLSKI, Janusz, MRSIC-KRMPOTIC, Zrinka, JAGIELLO-GRUSZFELD, Agnieszka, RIVA, Alessandro, BUYSE, Marc, TAUPIN, Henry, SAUTER, Guido, PRESS, Michael F, SLAMON, Dennis J, PEGRAM, Mark D, PIENKOWSKI, Tadeusz, EIERMANN, Wolfgang, VON MINCKWITZ, Gunter, ROCHE, Henri, MARTIN, Miguel, CROWN, John, MACKEY, John R

“…Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel,…”
Get full text

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer by Ladoire, Sylvain, Penault-Llorca, Frédérique, Senovilla, Laura, Dalban, Cécile, Enot, David, Locher, Clara, Prada, Nicole, Poirier-Colame, Vichnou, Chaba, Kariman, Arnould, Laurent, Ghiringhelli, François, Fumoleau, Pierre, Spielmann, Marc, Delaloge, Suzette, Poillot, Marie Laure, Arveux, Patrick, Goubar, Aicha, Andre, Fabrice, Zitvogel, Laurence, Kroemer, Guido

“…In spite of adjuvant chemotherapy, a significant fraction of patients with localized breast cancer (BC) relapse after optimal treatment. We determined the…”
Get full text

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial by ROCHE, Henri, FUMOLEAU, Pierre, VIENS, Patrice, MONNIER, Alain, VINDEVOGHEL, Anita, CAMPONE, Mario, GOUDIER, Marie-Josèphe, BONNETERRE, Jacques, FERRERO, Jean-Marc, MARTIN, Anne-Laure, GENEVE, Jean, ASSELAIN, Bernard, SPIELMANN, Marc, CANON, Jean-Luc, DELOZIER, Thierry, SERIN, Daniel, SYMANN, Michel, KERBRAT, Pierre, SOULIE, Patrick, EICHLER, Francoise

“…The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by…”
Get full text

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial by Goss, Paul E, Prof, Smith, Ian E, Prof, O'Shaughnessy, Joyce, MD, Ejlertsen, Bent, Prof, Kaufmann, Manfred, Prof, Boyle, Frances, MBBS, Buzdar, Aman U, Prof, Fumoleau, Pierre, Prof, Gradishar, William, Prof, Martin, Miguel, Prof, Moy, Beverly, MD, Piccart-Gebhart, Martine, MD, Pritchard, Kathleen I, Prof, Lindquist, Deborah, MD, Chavarri-Guerra, Yanin, MD, Aktan, Gursel, MD, Rappold, Erica, BSN, Williams, Lisa S, MSc, Finkelstein, Dianne M, Prof

“…Summary Background Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab—the standard adjuvant treatment. We…”
Get full text

Identification of molecular apocrine breast tumours by microarray analysis by FARMER, Pierre, BONNEFOI, Herve, DUSS, Stephan, NICOULAZ, Anne-Laure, BRISKEN, Cathrin, FICHE, Maryse, DELORENZI, Mauro, IGGO, Richard, BECETTE, Veronique, TUBIANA-HULIN, Michele, FUMOLEAU, Pierre, LARSIMONT, Denis, MACGROGAN, Gaetan, BERGH, Jonas, CAMERON, David, GOLDSTEIN, Darlene

“…Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of…”
Get full text

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer by THOMAS, Eva, TABERNERO, Josep, BASELGA, José, RIVERA, Edgardo, GUARNERI, Valentina, POULART, Valerie, KLIMOVSKY, Judith, LEBWOHL, David, MARTIN, Miguel, FORNIER, Monica, CONTE, Pierfranco, FUMOLEAU, Pierre, LLUCH, Ana, VAHDAT, Linda T, BUNNELL, Craig A, BURNS, Howard A, VIENS, Patrice

“…Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs…”
Get full text

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study by RAYMOND, Eric, BRANDES, Alba A, HEINRICH, Michael C, GORLIA, Thierry, LACOMBE, Denis, VAN DEN BENT, Martin J, DITTRICH, Christian, FUMOLEAU, Pierre, COUDERT, Bruno, CLEMENT, Paul M. J, FRENAY, Marc, RAMPLING, Roy, STUPP, Roger, KROS, Johan M

“…To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. This was a single-arm, phase II study. Eligible patients had recurrent…”
Get full text

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST by Depardon, Edouard, Kanoun, Salim, Humbert, Olivier, Bertaut, Aurélie, Riedinger, Jean-Marc, Tal, Ilan, Vrigneaud, Jean-Marc, Lasserre, Maud, Toubeau, Michel, Berriolo-Riedinger, Alina, Dygai-Cochet, Inna, Fumoleau, Pierre, Brunotte, François, Cochet, Alexandre

“…Evaluate response and predict prognosis of patients with newly diagnosed metastatic breast cancer treated with first line systemic therapy using European…”
Get full text

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results by O'SHAUGHNESSY, Joyce, MILES, David, TWELVES, Chris, VAN HAZEL, Guy, VERMA, Shailendra, LEONARD, Robert, VUKELJA, Svetislava, MOISEYENKO, Vladimir, AYOUB, Jean-Pierre, CERVANTES, Guadalupe, FUMOLEAU, Pierre, JONES, Stephen, LUI, Wing-Yiu, MAURIAC, Louis

“…Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in…”
Get full text

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations by CHEVRIER, SANDY, ARNOULD, LAURENT, GHIRINGHELLI, FRANÇOIS, COUDERT, BRUNO, FUMOLEAU, PIERRE, BOIDOT, ROMAIN

“…The development of targeted therapies in cancer has accelerated the development of molecular diagnosis. This new cancer discipline is booming, with an…”
Get full text

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial) by Penault-Llorca, Frédérique, Filleron, Thomas, Asselain, Bernard, Baehner, Frederick L, Fumoleau, Pierre, Lacroix-Triki, Magali, Anderson, Joseph M, Yoshizawa, Carl, Cherbavaz, Diana B, Shak, Steven, Roca, Lise, Sagan, Christine, Lemonnier, Jérôme, Martin, Anne-Laure, Roché, Henri

“…The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+)…”
Get full text

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy by Berriolo-Riedinger, Alina, Touzery, Claude, Riedinger, Jean-Marc, Toubeau, Michel, Coudert, Bruno, Arnould, Laurent, Boichot, Christophe, Cochet, Alexandre, Fumoleau, Pierre, Brunotte, François

“…To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete…”
Get full text